12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xalkori crizotinib: Phase I data

Data from 25 evaluable NSCLC patients who previously received 1 or 2 prior chemotherapy regimens in the Phase I portion of an open-label, U.S. Phase I/II trial showed that twice-daily 150 and 200 mg Xalkori in combination with Tarceva erlotinib produced 1 partial response with a duration of 61 weeks, plus 9 cases of stable disease (SD) with a duration of 7-54 weeks....

Read the full 305 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >